Business Model Breakdown
How Agios Pharmaceuticals Inc Makes Money
AGIO
Market Cap
$1.6B
Annual Revenue
$45M
Profit Margin
-764.0%
The Short Version
Agios Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare and severe diseases. It primarily makes money by researching, developing, manufacturing, and selling prescription drugs. Its current flagship product, PYRUKYND (mitapivat), is an oral activator of pyruvate kinase (PK) designed to treat various rare blood disorders, with its initial approval for pyruvate kinase deficiency and recent FDA approval for an unspecified indication in December 2025. The company generates revenue from direct product sales and potential licensing agreements for its pipeline candidates.
Where the Revenue Comes From
PYRUKYND product sales (~100% of current product revenue)
Potential milestone payments or royalties from collaboration agreements
Who buys: Patients diagnosed with rare blood disorders such as pyruvate kinase deficiency, thalassemia, and potentially sickle cell disease, through healthcare providers and specialty pharmacies.
Why It Works (Competitive Advantages)
- ✔Proprietary Pyruvate Kinase activator technology (mitapivat)
- ✔FDA-approved drug (PYRUKYND) with strong commercial growth
- ✔Established regulatory pathways for rare blood disorders
Economic Moat: Narrow (Intangible Assets/IP (patents protecting mitapivat), Switching Costs (for patients who respond well to existing therapies, though new therapies aim to replace existing ones), Regulatory Advantages (FDA approvals and accelerated pathways))
What Our Analysis Says
DVR Score as of April 22, 2026
Agios Pharmaceuticals Inc.'s potential for 10x growth has significantly improved since the last analysis. The most material change is the **absence of any mention of a securities fraud investigation**, a critical red flag cited previously. Furthermore, PYRUKYND (mitapivat) received FDA approval in December 2025 and demonstrated strong 86% YoY revenue growth in Q4 2025, validating its commercial potential. While the competitive threat from Novo Nordisk in sickle cell disease is a new headwind, Agios secured an accelerated approval pathway for mitapivat in SCD based on hemoglobin response. The company remains unprofitable and is burning cash, but losses are forecast to narrow. Analyst sentiment is largely positive with significant price target upside. The removal of severe legal risk and confirmation of commercial traction reposition Agios as a higher-risk, higher-reward growth opportunity, albeit with continued clinical and competitive challenges.